Cadila Pharma launches arthritis biosimilar drug Cadalimab in India
Cadalimab has shown to have significant reduction in signs and symptoms of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis.
Ahmedabad: Cadila Pharmaceuticals has recently announced the launch of Adalimumab biosimilar under the brand name Cadalimab™ for the domestic market.
Adalimumab is a disease-modifying antirheumatic drug and a monoclonal antibody that works by inactivating tumor necrosis factor-alpha (TNFα) recommended in the treatment of many diseases.
Adalimumab, popular under the brand name Humira® by Abbvie, is used to treat rheumatoid arthritis, psoriatic arthritis, Ankylosing Spondylitis and psoriasis.
Cadalimab™ is the fourth biosimilar launched in the last 2 months by Cadila Pharmaceuticals.
"Around 7 million* people in India suffer from rheumatoid arthritis, while 0.44-2.8%** of people in India suffer from Psoriasis. While these are not life-threatening, Psoriasis and RA can be painful to live with. With the launch of Cadalimab™, we want to reach these patients with a cost-effective solution and give them a chance at a better life." shared Amit Ajmera, Vice President, Cadila Pharmaceuticals Limited.
"With the launch of every product, we strengthen our core philosophy of providing quality medicines to all. Cadalimab™ comes in an easy pre-filled syringe which makes it easy to use for every patient and provides them relief from disorders such as arthritis and Psoriasis. We are on a journey to expand treatment options with affordable biosimilars", said Mr. O.P. Singh, President -Sales and Marketing, Cadila Pharmaceuticals Limited.
Cadalimab™ is available in 40mg/0.8ml injection and has shown to have significant reduction in signs and symptoms of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis after the usage of Cadalimab™.
Cadila Pharmaceuticals recently launched 3 more biosimilar products in the last 2 months under the name Bevaro™, Ritucad™ and NuPTH for treatment of cancer and osteoporosis. Cadila plans to launch multiple biosimilar products this year for the Indian Market.
Cadila Pharmaceuticals Ltd has recently concluded and cleared USFDA inspection successfully in February 2020.
Read also: Cadila Pharma Unveils Biosimilar Rituximab Under Brand Name Ritucad
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.